Becton, Dickinson and Company $BDX Stock Position Raised by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. lifted its position in Becton, Dickinson and Company (NYSE:BDX) by 0.5% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,040 shares of the medical instruments supplier’s stock after acquiring an additional 81 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Becton, Dickinson and Company were worth $2,763,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Northcape Wealth Management LLC increased its stake in Becton, Dickinson and Company by 0.5% in the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock valued at $2,248,000 after buying an additional 51 shares during the period. Diversified Trust Co increased its stake in Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock valued at $272,000 after buying an additional 53 shares during the period. Bill Few Associates Inc. increased its stake in Becton, Dickinson and Company by 0.7% in the 2nd quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock valued at $1,362,000 after buying an additional 55 shares during the period. Horizon Bancorp Inc. IN increased its stake in Becton, Dickinson and Company by 10.9% in the 1st quarter. Horizon Bancorp Inc. IN now owns 569 shares of the medical instruments supplier’s stock valued at $130,000 after buying an additional 56 shares during the period. Finally, Meadow Creek Wealth Advisors LLC increased its stake in Becton, Dickinson and Company by 5.4% in the 1st quarter. Meadow Creek Wealth Advisors LLC now owns 1,161 shares of the medical instruments supplier’s stock valued at $266,000 after buying an additional 59 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $189.20 on Monday. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm’s fifty day simple moving average is $190.60 and its 200 day simple moving average is $184.37. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $54.23 billion, a PE ratio of 34.03, a PEG ratio of 1.48 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion for the quarter. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were paid a $1.04 dividend. The ex-dividend date was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 74.82%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $211.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Piper Sandler restated a “neutral” rating and set a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $205.40.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders have sold 1,838 shares of company stock valued at $348,392. Company insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.